Ramiro Ribeiro Sells 2,437 Shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Eyepoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $14.11 on Wednesday. The firm has a market capitalization of $1.18 billion, a P/E ratio of -4.47 and a beta of 1.89. Eyepoint Pharmaceuticals, Inc. has a 1-year low of $5.30 and a 1-year high of $19.11. The business’s 50-day simple moving average is $14.52 and its 200-day simple moving average is $14.58.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.03). The company had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.01 million. Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%. On average, equities research analysts expect that Eyepoint Pharmaceuticals, Inc. will post -3.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of EYPT. Rhumbline Advisers increased its holdings in Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock worth $906,000 after purchasing an additional 9,548 shares during the last quarter. American Century Companies Inc. increased its holdings in Eyepoint Pharmaceuticals by 57.8% during the 2nd quarter. American Century Companies Inc. now owns 67,612 shares of the company’s stock worth $636,000 after purchasing an additional 24,752 shares during the last quarter. Invesco Ltd. increased its holdings in Eyepoint Pharmaceuticals by 199.8% during the 2nd quarter. Invesco Ltd. now owns 128,772 shares of the company’s stock worth $1,212,000 after purchasing an additional 85,824 shares during the last quarter. Raymond James Financial Inc. increased its holdings in Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after purchasing an additional 1,177 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its holdings in Eyepoint Pharmaceuticals by 9.7% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock worth $63,988,000 after purchasing an additional 600,000 shares during the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EYPT has been the topic of several recent research reports. HC Wainwright boosted their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Chardan Capital boosted their price target on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Citigroup boosted their price target on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $32.20.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.